|  | Unmatched | Propensity score matched | ||||
---|---|---|---|---|---|---|---|
Characteristic | Cohort (n = 922) | Inpatient Statin (n = 250) | Non Statin (n = 672) | p-value | Inpatient Statin (n = 229) | Non Statin (n = 229) | p-value |
Age, (years) n (%) | |||||||
 Median (IQR) | 66 (56–73.25) | 66 (59–75) | 65 (54–73) | 0.007 | 66 (58.5–75) | 68 (59–75) | 0.49 |
 18–30 | 26 (2.8) | 0 | 26 (3.9) | 0 | 5 (2.2) | ||
 31–45 | 81 (8.8) | 10 (4) | 71 (10.6) | 8 (3.5) | 20 (8.7) | ||
 46–64 | 320 (34.7) | 91 (36.4) | 229 (34.1) | 87 (38) | 63 (27.5) | ||
 ≥ 65 | 495 (53.7) | 149 (59.6) | 346 (51.5) | 134 (58.5) | 141 (61.6) | ||
Sex, n (%) | |||||||
 Male | 490 (53.1) | 139 (55.6) | 351 (52.2) | 0.36 | 123 (53.7) | 128 (55.9) | 0.64 |
 Female | 432 (46.9) | 111 (44.4) | 321 (47.8) | 106 (46.3) | 101 (44.1) | ||
Race, n (%) | |||||||
 Blacks | 688 (74.6) | 179 (71.6) | 509 (75.7) | 0.2 | 167 (72.9) | 172 (75.1) | 0.59 |
 Other races | 234 (25.4) | 71 (28.4) | 163 (24.3) | 62 (27.1) | 57 (24.9) | ||
BMI | |||||||
 Median (IQR) | 29.4 (25.2–35.9) | 29.25 (24.4–34.83) | 29.4 (25.6–36.5) | 0.17 | 29.7 (24.9–35.1) | 29.27 (25.65–35.35) | 0.78 |
 < 18.5 (underweight) | 28 (3) | 8 (3.2) | 20 (3) | 6 (2.6) | 8 (3.5) | ||
 18.5–24.9 (normal) | 195 (21.1) | 65 (26) | 130 (19.3) | 53 (23.1) | 44 (19.2) | ||
 25–29.9 (overweight) | 266 (28.9) | 61 (24.4) | 205 (30.5) | 57 (24.9) | 73 (31.9) | ||
 ≥ 30 (obese) | 432 (46.9) | 116 (46.4) | 316 (47) | 113 (49.3) | 104 (45.4) | ||
Comorbidities, n (%) | |||||||
 Preexisting lung diseases | 304 (33) | 87 (34.8) | 217 (32.3) | 0.47 | 81 (35.4) | 74 (32.3) | 0.49 |
 Coronary artery disease | 214 (23.2) | 94 (37.6) | 120 (17.9) |  < 0.001 | 86 (37.6) | 76 (33.2) | 0.33 |
 Hypertension | 756 (82) | 233 (93.2) | 523 (77.8) |  < 0.001 | 213 (93) | 200 (87.3) | 0.04 |
 Diabetes Mellitus | 413 (44.8) | 136 (54.4) | 277 (41.2) |  < 0.001 | 126 (55) | 119 (52) | 0.51 |
 Hyperlipidemia | 280 (30.4) | 127 (50.8) | 153 (22.8) |  < 0.001 | 109 (47.6) | 101 (44.1) | 0.45 |
 Congestive Heart Failure | 135 (14.6) | 56 (22.4) | 79 (11.8) |  < 0.001 | 51 (22.3) | 46 (20.1) | 0.57 |
 Stroke | 100 (10.8) | 48 (19.2) | 52 (7.7) |  < 0.001 | 39 (17) | 37 (16.2) | 0.8 |
 Cancer | 88 (9.5) | 18 (7.2) | 70 (10.4) | 0.14 | 18 (7.9) | 16 (7) | 0.72 |
 Chronic liver disease | 35 (3.8) | 3 (1.2) | 32 (4.8) | 0.01 | 3 (1.3) | 5 (2.2) | 0.48 |
 Chronic kidney disease | 110 (11.9) | 41 (16.4) | 69 (10.3) | 0.01 | 36 (15.7) | 37 (16.2) | 0.9 |
 ESRD on dialysis | 98 (10.6) | 31 (12.4) | 67 (10) | 0.29 | 30 (13.1) | 20 (8.8) | 0.13 |
 Smoking | 387 (42) | 117 (46.8) | 270 (40.2) | 0.07 | 103 (45) | 112 (48.9) | 0.4 |
Insurance | |||||||
 Uninsured | 9 (1) | 3 (1.2) | 6 (0.9) | 0.03 | 3 (1.3) | 4 (1.7) | 0.83 |
 Medicaid | 242 (26.2) | 52 (20.8) | 190 (28.3) | 50 (21.8) | 45 (19.7) | ||
 Medicare | 595 (64.5) | 180 (72) | 415 (61.8) | 161 (70.3) | 168 (73.4) | ||
 Private | 76 (8.2) | 15 (6) | 61 (9.1) | 15 (6.6) | 12 (5.2) | ||
Days from symptom onset to hospital presentation | |||||||
 0–5 | 649 (70.4) | 185 (74) | 464 (69) | 0.2 | 173 (75.5) | 168 (73.4) | 0.78 |
 6–10 | 160 (917.4) | 39 (15.6) | 121 (18) | 39 (17) | 39 (17) | ||
 11–15 | 55 (6) | 10 (4) | 45 (6.7) | 10 (4.4) | 15 (6.6) | ||
 16 +  | 18 (2) | 7 (2.8) | 11 (1.6) | 7 (3.1) | 7 (3.1) | ||
CURB-65 at presentation | |||||||
 0 | 222 (24.1) | 36 (14.4) | 186 (27.7) |  < 0.001 | 35 (15.3) | 44 (19.2) | 0.44 |
 1 | 280 (30.4) | 81 (32.4) | 199 (29.6) | 76 (33.2) | 62 (27.1) | ||
 2 | 275 (29.8) | 88 (35.2) | 187 (27.8) | 82 (35.8) | 80 (34.9) | ||
 3 | 110 (11.9) | 38 (15.2) | 72 (10.7) | 30 (13.1) | 32 (14) | ||
 4 | 20 (2.2) | 4 (1.6) | 16 (2.4) | 3 (1.3) | 8 (3.5) | ||
 5 | 12 (1.3) | 3 (1.2) | 9 (1.3) | 3 (1.3) | 3 91.3) |